As OpenAI commits to deploying 6 gigawatts of AMD GPUs and developers grapple with AI-generated code vulnerabilities, the AI industry faces a critical infrastructure and security reckoning.

The Infrastructure Race Heats Up: AMD's 6-Gigawatt Bet and the Hidden Costs of AI's Growing Pains

As reinforcement learning accelerates progress in specific AI domains, a technical gap is emerging that could reshape which AI capabilities advance—and which get left behind.

The Reinforcement Learning Divide: Why AI Progress Is Becoming Uneven

For the first time in startup history, AI companies are capturing more than half of all venture capital dollars, fundamentally reshaping what gets funded and built.

The Great AI Capital Shift: How Machine Learning Crossed the 50% Threshold in Venture Funding

A breakthrough in AI-assisted drug discovery demonstrates how machine learning can dramatically accelerate understanding of drug mechanisms, while major tech players position for AI's next phase.

AI Reshapes Drug Discovery as MIT and McMaster Map Antibiotic Mechanism with Machine Learning

Major players are repositioning with OpenAI acquiring consumer AI talent while a new hardware startup threatens Nvidia's AI chip dominance.

AI Industry Shifts: OpenAI's Consumer Focus and Novel Hardware Challenges Nvidia

Recent developments show a clear pivot toward multi-agent AI systems that can collaborate, reason, and conduct autonomous research, with particular breakthroughs in drug discovery and scientific automation

AI Research Shifts from Models to Agents: Multi-Agent Systems Show Promise in Drug Discovery and Scientific Research

Major tech players are making billion-dollar bets on AI infrastructure while new research suggests ways to make AI systems more efficient and practical.